Ares Financial Consulting
RYTM icon

Ares Financial Consulting’s Rhythm Pharmaceuticals RYTM Stock Holding History

Ares Financial Consulting’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-5
Closed -$555 – 1125
2026
Q2 		$555 Buy
+5
New +$452 ﹤0.01% 1082

Other funds holding RYTM

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Ares Financial Consulting's RYTM Position: Q3 2026 in Review

Ares Financial Consulting sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2026, closing a stake of 5 shares — an estimated $555 sold.

Ares Financial Consulting first reported a position in RYTM in Q2 2026 and held it in 1 quarter. The position peaked at $555 in Q2 2026. 125 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • Ares Financial Consulting reported no remaining Rhythm Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Ares Financial Consulting sold 5 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $555.
  • Ares Financial Consulting first reported a position in Rhythm Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Ares Financial Consulting's Rhythm Pharmaceuticals position peaked at $555 in Q2 2026.
  • 125 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.